HAVCR2 and ovarian cancer: Moreover, the efficacy of both carboplatin (100 mg/kg) and paclitaxel (10 mg/kg) against mouse ID8 ovarian cancers established intraperitoneally has been shown to remain unaltered by the concomitant administration of an ICI targeting hepatitis A virus cellular receptor 2 (HAVCR2, also known as TIM-3) [92].